Standout Papers

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer 2017 2026 2020 2023 883
  1. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (2017)
    Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine
  2. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024)
    Aditya Bardia, Xichun Hu et al. New England Journal of Medicine
  3. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). (2024)
    Giuseppe Curigliano, Xichun Hu et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 7 from Science/Nature 61 standout
Sub-graph 1 of 22

Citing Papers

Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
5 intermediate papers

Works of Christelle Lévy being referenced

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
2017 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Christelle Lévy 1848 1149 1063 139 2.9k
Laura M. Spring 2094 1279 1162 126 3.3k
Neelima Denduluri 1642 668 788 67 2.7k
Naoki Niikura 1641 874 880 146 2.3k
Rashmi K. Murthy 2203 955 579 85 2.8k
Kevin Kalinsky 2035 959 703 141 3.0k
Philippe Aftimos 1834 783 757 142 2.9k
Juan de la Haba-Rodríguez 2981 979 1745 123 3.8k
Mafalda Oliveira 1407 1034 859 170 2.1k
Alvaro Moreno‐Aspitia 1845 650 761 105 2.7k
Jerry Younger 2622 1450 784 58 3.8k

All Works

Loading papers...

Rankless by CCL
2026